Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Why Am I Gaining Weight on GLP-1 Weight Loss Medication
TanYZhouJLiuCZhouPShengZLiJet al
The landmark cardiovascular outcomes trialsincluding SUSTAIN-6 for semaglutide and LEADER for liraglutidespecifically evaluated cardiovascular safety endpoints and did not report increased rates of venous thromboembolism compared to placebo, though it's important to note that VTE was not a primary endpoint in these studies
What blood tests should I ask for
Pevec et al., 2010) and worsening, as well as immunosuppression (Sikiric et al., 2003)
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis MARKET DYNAMICS Stringent cost and payer controls OPPORTUNITIES Impact Level Increasing studies on oral GLP-1 Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis Rapid expansion of manufacturing capacity is driving growth across the pharmaceutical market, especially for high-demand drugs like GLP-1 analogs
